Substance / Medication

Cyclothiazide

Overview

Active Ingredient
cyclothiazide
RxNorm CUI
22033

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Research Evidence

Published studies and systematic reviews

Sort:
Trafficking of presynaptic AMPA receptors mediating neurotransmitter release: neuronal selectivity and relationships with sensitivity to cyclothiazide.
Pittaluga Anna, Feligioni Marco, Longordo Fabio et al. · Neuropharmacology · 2006
PMID: 16242162Observational
Cyclothiazide induces robust epileptiform activity in rat hippocampal neurons both in vitro and in vivo.
Qi Jinshun, Wang Yun, Jiang Min et al. · J Physiol · 2006
PMID: 16423850ObservationalFull text (PMC)
Downregulated GABA and BDNF-TrkB pathway in chronic cyclothiazide seizure model.
Kong Shuzhen, Cheng Zhihua, Liu Jianhui et al. · Neural Plast · 2014
PMID: 24757570PreclinicalFull text (PMC)
Cyclothiazide-induced persistent increase in respiratory-related activity in vitro.
Babiec Walter E, Faull Kym F, Feldman Jack L · J Physiol · 2012
PMID: 22753547PreclinicalFull text (PMC)
Cyclothiazide induces seizure behavior in freely moving rats.
Kong Shuzhen, Qian Binbin, Liu Jianhui et al. · Brain Res · 2010
PMID: 20678492PreclinicalFull text (PMC)
BDNF-TrkB signaling pathway mediates the induction of epileptiform activity induced by a convulsant drug cyclothiazide.
Wang Yun, Qi Jin-Shun, Kong Shuzhen et al. · Neuropharmacology · 2009
PMID: 19393251PreclinicalFull text (PMC)
Distinct structural features of cyclothiazide are responsible for effects on peak current amplitude and desensitization kinetics at iGluR2.
Hald Helle, Ahring Philip K, Timmermann Daniel B et al. · J Mol Biol · 2009
PMID: 19591837Preclinical
Cyclothiazide binding to the GABAA receptor.
Szárics Eva, Simon Agnes, Visy Júlia et al. · Neurosci Lett · 2008
PMID: 18502046Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Cyclothiazide (substance)
SNOMED CT
37006008
UMLS CUI
C0056831
RxNorm CUI
22033

Clinical Data

This intervention maps to 10 entities in the Ltrl knowledge graph.

3
Conditions
4
Biomarkers
2
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.